



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/804,710

03/19/2004

George DeStefano

09-0277

7531

28509

7590

04/28/2009

MICHAEL P. MORRIS

BOEHRINGER INGELHEIM USA CORPORATION

900 RIDGEBURY ROAD

P O BOX 368

RIDGEFIELD, CT 06877-0368

EXAMINER

HAGHIGHATIAN, MINA

ART UNIT

PAPER NUMBER

1616

MAIL DATE

DELIVERY MODE

04/28/2009

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/804,710	Applicant(s) DESTEFANO ET AL.	
	Examiner MINA HAGHIGHATIAN	Art Unit 1616	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 02/13/09.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1,2 and 4-11 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-2, 4-11 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Receipt is acknowledged of the Remarks filed on 02/13/09. Claims 1, 4 and 6 have been amended, claim 3 has been cancelled and new claims 8-11 have been added. Accordingly, claims **1-2 and 4-11** are pending.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 1-2, 4 and 6 are rejected under 35 U.S.C. 103(a) as being unpatentable over Adjei et al (US 6,261,539).

Adjei et al teach medicinal formulations containing a particulate drug, a propellant and a stabilizing agent comprising a water addition (see abstract and col. 2, lines 42-45). Suitable medicaments include albuterol and ipratropium bromide (see col. 2, lines

Art Unit: 1616

54-58). Suitable propellants include HFA 134a and HFA 227 (see col. 3, lines 32-45). Suitable stabilizer is a water addition (see col. 3, line 47-58). It is also disclosed that generally the formulation comprises about 300 ppm water and an amount of from 300 to 2000 ppm water is added as a stabilizer (col. 4, lines 8-20 and claim 7). Suitable co-solvent is ethanol (see col. 2, lines 30-33). Conventional lubricants, surfactants and co-solvents can be added (col. 4, lines 34-38).

Adjei also discloses that "An aerosol formulation preferably comprises the water addition in an amount effective to stabilize the formulation relative to an identical formulation not containing the water addition i.e. containing only nascent formulation water, such that the drug does not settle, cream or flocculate after agitation so quickly as to prevent reproducible dosing of the drug (see col. 3, lines 59-65). Adjei further discloses that the water addition must be present in a formulation in an amount in excess of the concentration of the nascent formulation water (see col. 4, lines 8-29).

While Adjei does not anticipate the claimed formulation because the specific range of water is not disclosed, Adjei teaches the same formulations and that addition of a small amount of water to the formulations provides stability to the formulations. The water is added as a stabilizer. The claimed concentration range of 0.13 to 0.18% is within the disclosed range of 0.03 to 0.2% (300 to 2000 ppm). It would have been obvious to one of ordinary skill in the art at the time the invention was made to have selected the suitable amount of water as disclosed by Adjei according to the active agent and other excipients in the formulation. Thus, regarding the claimed ranges, it is

considered that where the claimed ranges "overlap or lie inside ranges disclosed by the prior art" a *prima facie* case of obviousness exists. See MPEP 2144.05 [R-5].

It has also been decided that "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." *In re Aller*, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955); see also *Peterson*, 315 F.3d at 1330, 65 USPQ2d at 1382 ("The normal desire of scientists or artisans to improve upon what is already generally known provides the motivation to determine where in a disclosed set of percentage ranges is the optimum combination of percentages."); *In re Hoeschele*, 406 F.2d 1403, 160 USPQ 809 (CCPA 1969); *Merck & Co. Inc. v. Biocraft Laboratories Inc.*, 874 F.2d 804, 10 USPQ2d 1843 (Fed. Cir.), cert. denied, 493 U.S. 975 (1989); *In re Kulling*, 897 F.2d 1147, 14 USPQ2d 1056 (Fed.Cir. 1990); and *In re Geisler*, 116 F.3d 1465, 43 USPQ2d 1362 (Fed. Cir. 1997). See MPEP 2144.05.

Claims 1-2, 4 and 6 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lewis et al (EP 1219293).

Lewis et al teach a composition for use in an aerosol inhaler comprising an active agent, an HFA propellant and a cosolvent. Cosolvents include alcohols such as **ethanol** and propellants include HFA 134a and HFA 227 (see [0012] and [0010]). The active agents may be any one or more salbutamol (also known as albuterol), ipratropium bromide, beclomethasone, etc (see [0064]). The formulations may include a

Art Unit: 1616

low volatility component such as **polyvinyl pyrrolidone** (see 0056)]. Other suitable low volatility materials include saturated and unsaturated carboxylic acids such as ascorbic acid (see [0055]).

Lewis also discloses the method of making the formulation and filling the aerosol inhaler. The method includes filling the container with a) one or more active materials, b) One or more low volatility components, c) One or more co-solvents followed by the addition of the HFA propellant. The formulations are said to contain up to 0.5% water and Table 2, discloses four formulations two of which contain **0.1% water**.

While Lewis et al does not anticipate the claimed formulation because the specific range of water is not disclosed, Lewis et al teach the same formulations and that addition of a small amount of water to the formulations provides stability to the formulations. Lewis et al teach the broader range of up to 0.5% and exemplify formulations that contain 0.1%. The cited "0.1%" by Lewis et al could potentially be the rounded amount of 0.1 to <0.2%, which includes 0.13 to 0.18%. Even if this is not the interpretation given to the disclosure, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have selected the suitable amount of water as disclosed by Lewis et al according to the active agent and other excipients in the formulation. Thus, regarding the claimed ranges, it is considered that where the claimed ranges "overlap or lie inside ranges disclosed by the prior art" a *prima facie* case of obviousness exists. See MPEP 2144.05 [R-5].

It has also been decided that “[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.” *In re Aller*, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955); see also *Peterson*, 315 F.3d at 1330, 65 USPQ2d at 1382 (“The normal desire of scientists or artisans to improve upon what is already generally known provides the motivation to determine where in a disclosed set of percentage ranges is the optimum combination of percentages.”); *In re Hoeschele*, 406 F.2d 1403, 160 USPQ 809 (CCPA 1969); *Merck & Co. Inc. v. Biocraft Laboratories Inc.*, 874 F.2d 804, 10 USPQ2d 1843 (Fed. Cir.), cert. denied, 493 U.S. 975 (1989); *In re Kulling*, 897 F.2d 1147, 14 USPQ2d 1056 (Fed.Cir. 1990); and *In re Geisler*, 116 F.3d 1465, 43 USPQ2d 1362 (Fed. Cir. 1997). See MPEP 2144.05.

Claims 1-2, 4 and 6 are rejected under 35 U.S.C. 103(a) as being unpatentable over Ashurst et al (6,511,652).

Ashurst et al teach a metered dose inhaler having part or all of its internal surfaces coated with one or more fluorocarbon polymers for dispensing an inhalation drug formulation comprising beclomethasone dipropionate, a propellant in combination with other active agents and one or more excipients (see abstract and summary). The co-solvent is preferably an alcohol such as **ethanol** (col. 2, lines 60-66). Suitable active agents include **salbutamol**, **ipratropium**, etc or combinations thereof. Suitable propellants include **HFA 134a or HFA 227** (col. 3, lines 5-50).

Ashurst et al also discloses that the said formulation preferably contain at least 0.015%, e.g. 0.015 to 0.1% water by weight of the formulation (col. 5, lines 24-39).

While Ashurst et al does not anticipate the claimed formulation because the specific range of water is not disclosed, Ashurst et al teach the same formulations and the addition of a small amount of water to the formulations. Ashurst et al teach the broader range of at least 0.015% and exemplify formulations that contain 0.015 to 0.1%. It would have been obvious to one of ordinary skill in the art at the time the invention was made to have selected the suitable amount of water as disclosed by Ashurst et al according to the active agent and other excipients in the formulation. Thus, regarding the claimed ranges, it is considered that where the claimed ranges "overlap or lie inside ranges disclosed by the prior art" a *prima facie* case of obviousness exists. See MPEP 2144.05 [R-5].

It has also been decided that "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." *In re Aller*, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955); see also *Peterson*, 315 F.3d at 1330, 65 USPQ2d at 1382 ("The normal desire of scientists or artisans to improve upon what is already generally known provides the motivation to determine where in a disclosed set of percentage ranges is the optimum combination of percentages."); *In re Hoeschele*, 406 F.2d 1403, 160 USPQ 809 (CCPA 1969); *Merck & Co. Inc. v. Biocraft Laboratories Inc.*, 874 F.2d 804, 10 USPQ2d 1843 (Fed. Cir.), cert. denied, 493 U.S. 975 (1989); *In re Kulling*, 897 F.2d 1147, 14 USPQ2d

1056 (Fed.Cir. 1990); and *In re Geisler*, 116 F.3d 1465, 43 USPQ2d 1362 (Fed. Cir. 1997). See MPEP 2144.05.

Claims 1-2, 4 and 6 are rejected under 35 U.S.C. 103(a) as being unpatentable over by Keller et al (6,475,467).

Keller et al teach suspension formulations for delivery by metered dose inhalers comprising active agents in particulate form. It is disclosed that in such formulations the amount of **water** is less than 1% by weight (see col. 3, lines 55-67). The active agents suitable for the said formulations include ipratropium bromide, salmeterol, mometasone, etc. Formulations may comprise **two or more active agents** (col. 5, lines 20-45). Examples of preferred co-solvents include **ethanol** (col. 9, lines 1-10). Formulations may contain a buffer substance such as **citric acid** (col. 9, lines 29-35). Suitable propellants include HFA 134a and HFA 227 (col. 7, lines 54-60).

Keller et al does not anticipate the claimed formulation because the specific range of water is not disclosed, however, Keller et al's formulation comprise less than 1% water. While the range of less than 1% is a broader range compared to the specific range of 0.13 to 0.18% as claimed, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have selected the suitable amount of water as disclosed by Keller et al according to the active agent and other excipients in the formulation. Thus, regarding the claimed ranges, it is considered that where the claimed

ranges "overlap or lie inside ranges disclosed by the prior art" a *prima facie* case of obviousness exists. See MPEP 2144.05 [R-5].

It has also been decided that "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation." *In re Aller*, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955); see also *Peterson*, 315 F.3d at 1330, 65 USPQ2d at 1382 ("The normal desire of scientists or artisans to improve upon what is already generally known provides the motivation to determine where in a disclosed set of percentage ranges is the optimum combination of percentages."); *In re Hoeschele*, 406 F.2d 1403, 160 USPQ 809 (CCPA 1969); *Merck & Co. Inc. v. Biocraft Laboratories Inc.*, 874 F.2d 804, 10 USPQ2d 1843 (Fed. Cir.), cert. denied, 493 U.S. 975 (1989); *In re Kulling*, 897 F.2d 1147, 14 USPQ2d 1056 (Fed.Cir. 1990); and *In re Geisler*, 116 F.3d 1465, 43 USPQ2d 1362 (Fed. Cir. 1997). See MPEP 2144.05.

Claims 5 and 7-11 are rejected under 35 U.S.C. 103(a) as being unpatentable over Adjei et al in view of Jager et al (WO 9413262).

Adjei et al, discussed above, lacks specific disclosure on addition of citric acid.

Jager et al teach stabilized medicinal aerosol solution formulations comprising medicaments that degrade or decompose by interaction with solvents or water, an HFC propellant, a cosolvent and an acid (see abstract). Most preferred medicaments for use in the said aerosol solution formulations include **ipratropium bromide and albuterol**

Art Unit: 1616

(see page 8, lines 3-8). The suitable cosolvents include ethyl alcohol, polyethylene glycol, glycerol, etc. Most preferred cosolvent is **ethanol** (see page 9, line 17 to col. 10, line 11). The disclosed formulations contain an acid to prevent degradation. Suitable acids include ascorbic acid and **citric acid**, and the most preferred acid is citric acid (page 10, lines 17-32). Table 1 discloses a formulation comprising ipratropium bromide monohydrate, ethanol, HFA 134a, acid and water in the amount of 0.0 to 5%.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to have combined formulations and method of making them as taught by Adjei et al and Jager et al and end up with the claimed formulations. Alternatively, it would have been obvious to one of ordinary skill in the art given the general teachings of Adjei et al on the formulations, to have looked in the art for other suitable excipients such as stabilizers like, citric acid as taught by Jager et al with the reasonable expectations of successfully preparing stable and effective formulations for aerosol administration. In other words, all the claimed elements were known in the prior art and one skilled in the art could have combined the elements as claimed by known methods with no change in their respective functions, and the combination would have yielded predictable results to one of ordinary skill in the art at the time of the invention.

Claims 5 and 7-11 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lewis et al (EP 1219293) in view of Jager et al (WO 9413262).

Lewis et al and Jager et al are discussed above. Lewis et al discloses all the components of the instant claims except for citric acid. While disclosing addition of carboxylic acids such as ascorbic acid, lacks specific disclosure on citric acid.

Jager et al teaches the addition of an acid such as citric acid to the formulations as a stabilizer and a buffer.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to have combined formulations and method of making them as taught by Lewis et al and Jager et al and end up with the claims formulations. Alternatively, it would have been obvious to one of ordinary skill in the art given the general teachings of Lewis et al on the formulations and method of making them, to have looked in the art for specific carboxylic acids such as citric acid as taught by Jager et al with the reasonable expectations of successfully preparing stable and effective formulations for aerosol administration. In other words, the claims would have been obvious because a person of ordinary skill in the art would have been motivated to combine the prior art to achieve the claimed invention and that there would have been a reasonable expectation of success.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct

Art Unit: 1616

from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims **1-2, 4-11** are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-11 of U.S. Patent No. 6,423,298 in view of Adjei et al (US 6,261,539). Although the conflicting claims are not identical, they are not patentably distinct from each other because the claims of the instant Application would have been obvious over the claims of the U.S. Patent '298 in view of Adjei et al '539. Specifically, the instant claims and the reference claims are drawn to a formulation comprising an HFA propellant, one or more active agents and one or more excipients. The instant claims additionally require 0.13 to 0.18% water and reference claims do not require water. Adjei et al discloses similar formulations and teaches that the addition of a small amount of water from 300 to 2000 ppm, would improve stability of the formulations. Thus it would have been obvious to one of ordinary skill in the art to have implemented the teachings of Adjei et al on water addition, as a stabilizer in the formulations of the reference claims with a reasonable success.

Response to Arguments

Applicant's arguments filed 02/13/09 have been fully considered but they are not persuasive.

Applicant's main argument appears to be that none of the references applied in the rejection of claims 1-7 teach the specific water concentration range of 0.13 to 0.18%. Applicant then concludes that none of the references can properly anticipate the narrow range of the instant claims. Applicant also argues that Adjei does not teach a combination of albuterol and ipratropium. While this is correct, the argument is not persuasive because Adjei teaches the medicament can be any of the actives suitable for inhalation such as albuterol and ipratropium bromide. Adjei also claims a combination of medicaments for example in claims 5 and 12. Thus it would have been obvious to one of ordinary skill in the art to have combined the medicaments as needed for the treatments.

Applicants also argue that Examiner has not interpreted the data in the Declaration of George DeStefano properly. Applicants state that Examiner has incorrectly compared the amount of active ingredients present in one actuation event from three cans, each can having a different water content. Applicants state that "Examiner should compare, as applicants have previously done to show the unexpected results, reproducibility in a single "can" containing a specific water content (i.e. 2500 ppm) to repeatedly provide the same amount of the active ingredients released from the same "can" over a series of single actuation events as compared to a "can" containing a different water content (i.e. 1500 ppm)". Applicants also point to figures 2 and 3 of the

Declaration, which show the results of the reproducibility for “cans” containing various water contents to release the same amount of albuterol sulfate (i.e. % of theory) during a single actuation event.

The arguments are not persuasive, 1) because the argued preferred range is within the range of prior art such as Adjei (300-2000 ppm) and Lewis et al (up to 0.5% and examples of 0.1%). Also Adjei specifically teaches adding the said amount of water as a stabilizer for the formulation. 2) Applicant's arguments regarding better results when water content is from 0.13 to 0.18% (the specific range) is not found persuasive. While the two Figures (2 and 3) show that the range of 1200 to 1500 ppm water produces better results, the remaining data does not support applicants assertion. For example, the can containing 2500 ppm water also showed at or above target of reproducibility. Also at 0 and 800 ppm reproducibility is at 125% of target. For better illustration, we can also look at Tables 4-7 which show single reproducibility of upright and inverted samples at different water content for both albuterol sulfate and ipratropium bromide. We will consider at random, % reproducibility of actuation 1, week 1, for ipratropium bromide of cans containing 1000, 1200, 1500 and 2500 ppm water respectively. The said % theory is from inverted-5. The % reproducibility values are: 96.17, 99.50, 95.39 and 96.72. As can be seen there is no significant difference between the above values. In fact the can containing 1500 ppm, which is from the claimed range of 0.13% to 0.18%, has the lowest % reproducibility of the 4 cans tested. The same values for an upright (Up-5) are: 95.13, 101.78, 98.04 and 95.55. Again the stated values are not significantly different. Similar values for albuterol sulfate, actuation

Art Unit: 1616

2, Week 3, Up-5 are N/A, 135.15, 110.49 and 100.06 respectively. There are no values stated for 1000 ppm, and 1200 ppm showed the best results, while there is no significant difference between, for example, 100.06 and 110.49 (for albuterol). There is even less distinction shown between 102.19 and 100.93 (for Inv-5). Thus it is the Examiner's position that no unexpected results have been shown and that references teaching a water content the overlaps the cited ranges meets the claim ranges.

Claims 1-2, 4-11 are rejected.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MINA HAGHIGHATIAN whose telephone number is (571)272-0615. The examiner can normally be reached on core office hours.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Johann Richter can be reached on 571-272-0646. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Mina Haghighatian/

Mina Haghighatian
Primary Examiner
Art Unit 1616

Application/Control Number: 10/804,710
Art Unit: 1616

Page 17